http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0100704-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afc5d8c9ee6673323cee3e2d19bc5146 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 |
| filingDate | 1999-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0503072c90838a73d4befe2fc3c3bd88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58212e8ff1b6f3a50ea1d3e101763c3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2929e3fa1e4e06918c24599f767fc49 |
| publicationDate | 2001-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0100704-A2 |
| titleOfInvention | Alpha 1A receptor antagonist phthalimido arylpiperazines, which are useful for the treatment of benign prostatic hyperplasia |
| abstract | The present invention relates to phthalimido arylpiperazine alpha 1a receptor antagonists for the treatment of benign prostatic hyperplasia. The present invention relates to heterocyclic substituted piperazines of formula (I), to pharmaceutical compositions containing the compounds and to intermediates used in their preparation. The compounds of the invention selectively inhibit α1a adrenergic receptor binding. This receptor plays a role in benign prostatic hyperplasia. The compounds are useful in the treatment of this disease. In the formula (I), the substituents are as follows: R 1 is hydrogen or halogen, C 1-5 -alkoxy, hydroxy or C 1-5 -alkyl; R2 is optionally substituted C1-C6 alkyl, phenyl or phenyl (C1-C5 alkyl); R3 is hydrogen, hydroxy or C1-C5 alkoxy; R4 is hydrogen, C1-C5 alkyl, phenyl or phenyl (C1-C5 alkyl); R5, R6 and R7 are hydrogen, halogen, hydroxy or optionally substituted C1-C8-alkyl, or C1-C5-alkoxy, amino, alkylcarbonyl or alkoxycarbonyl; A, B, E are N or C, with the proviso that only one of them is N. SHE |
| priorityDate | 1998-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 151.